Aroa Biosurgery Limited was named a nominee for the 2026 Innovative Technology Program Excellence Award by Vizient.

Aroa Biosurgery is a soft-tissue regeneration company that develops, manufactures, sells and distributes medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Committed to ‘unlocking regenerative healing for everybody’, AROA’s products are developed from the Company’s proprietary AROA ECM™ Technology, a novel extracellular matrix biomaterial derived from ovine (sheep) forestomach. The company was founded in February 2008 based on intellectual property relating to the use of a novel form of ECM isolated from forestomach extracellular matrix for use in tissue regeneration applications. AROA is unlocking regenerative healing for everybody. AROA’s products make a meaningful impact for patients, surgeons and clinicians. AROA delivers high quality, simple to use products that significantly improve outcomes. AROA also believes its products should be widely accessible, affordable and change the standard of care for many patients. Maori for ‘understanding’, AROA is at the forefront of understanding how biology, structural form and human factors can unlock the body’s intrinsic power to heal.

Founded 2008